Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant in Methamphetamine Use Disorder
NCT05711862Phase 2Terminated
- Sponsor
- UTHealth Houston
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of suvorexant in methamphetamine use disorder (MUD), sponsored by UTHealth Houston. Started Mar 2023; status: terminated.
02
Drugs
suvorexant
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT05711862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05711862.